Frisch Financial Group Inc. Acquires Shares of 990 Amgen Inc. (NASDAQ:AMGN)

Frisch Financial Group Inc. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 990 shares of the medical research company’s stock, valued at approximately $266,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Morgan Stanley boosted its stake in Amgen by 12.9% during the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 3.2% during the 2nd quarter. Geode Capital Management LLC now owns 11,799,183 shares of the medical research company’s stock worth $2,613,646,000 after acquiring an additional 368,924 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Amgen by 4.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 11,241,858 shares of the medical research company’s stock worth $2,495,917,000 after acquiring an additional 480,421 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its stake in shares of Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after acquiring an additional 7,532,031 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after acquiring an additional 255,463 shares in the last quarter. 74.44% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,096 shares of Amgen stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $273.03, for a total value of $572,270.88. Following the completion of the transaction, the senior vice president now owns 10,874 shares in the company, valued at $2,968,928.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Amgen Price Performance

NASDAQ AMGN traded down $1.03 during trading on Wednesday, reaching $277.46. 3,026,313 shares of the company traded hands, compared to its average volume of 3,012,291. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock’s 50 day moving average price is $298.32 and its two-hundred day moving average price is $278.24. The company has a market cap of $148.70 billion, a price-to-earnings ratio of 22.25, a P/E/G ratio of 2.78 and a beta of 0.62. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter in the previous year, the company posted $4.09 earnings per share. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Stockholders of record on Friday, February 16th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.24%. This is a boost from Amgen’s previous quarterly dividend of $2.13. Amgen’s payout ratio is 72.06%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Amgen in a research note on Thursday, November 9th. They set a “hold” rating and a $240.00 price objective for the company. SVB Leerink lowered Amgen from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Oppenheimer reissued an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. Royal Bank of Canada raised their price objective on Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average price target of $295.30.

View Our Latest Stock Report on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.